TARGET PharmaSolutions

TARGET PharmaSolutions

TARGET PharmaSolutions was founded to address the high failure rate of clinical trials due to slow patient enrollment and poor data integration. The company’s platform combines electronic health records, claims data, and pharmacy records to create a comprehensive view of patient populations for rare diseases and oncology indications. By offering a pre-competitive data-sharing consortium, it enables pharmaceutical companies to identify eligible trial sites and patients faster than traditional methods. The firm’s strategy centers on data licensing, consortium subscriptions, and analytics services for top-tier pharmaceutical and biotech sponsors. Its platform covers over 300 million electronic health records in the United States and has been deployed across multiple therapeutic areas including nonalcoholic steatohepatitis (NASH), amyotrophic lateral sclerosis (ALS), and multiple rare genetic conditions. TARGET PharmaSolutions also partners with academic medical centers and contract research organizations to expand its data network. Headquartered in Durham, North Carolina, a hub for life sciences and clinical research, the firm employs a team of data scientists, software engineers, and domain experts. No public disclosures of ownership structure or parent company are available, and its funding history remains private. The firm has not publicly disclosed any clients or specific financial metrics. TARGET PharmaSolutions’ structural differentiator is its consortium-based data aggregation model, which operates across competing sponsors — a model that avoids the conflict of interest inherent in single-sponsor data solutions while creating a defensible dataset. This governance structure allows it to offer standardized datasets and benchmarks that no individual pharma company can replicate in-house.